Inducing Staphylococcus epidermidis (SE) Strain Isolated from the Microbiome of a Healthy Human Subject
Diabetic peripheral neuropathy (DPN) is a common complication of diabetes, affecting up to 50% of patients with prolonged diabetes. It results from nerve damage caused by high blood sugar levels, leading to symptoms like pain, numbness, and tingling in the legs, feet, hands, or arms. Severe cases may cause foot ulcers or amputations.
We are developing a novel biotherapeutic called SELTA, a first-in-class molecule with the unique ability to simultaneously modulate both immune cells and nerve cells to modify inflammatory disease and induce non-opioid analgesia.
SELTA is a TLR2/6 agonist derived from the normal microbial flora of a healthy individual, suggesting the potential for limited off-target effects and toxicity.
Downstream TLR2/6 signaling after SELTA leads to anti-inflammatory and analgesic effects.
Well-defined path to proof of concept:
Potential to be first-in-class molecule targeting TLR2/6 for auto-immune diseases.
Novel TLR2/6 agonist with dual mechanism of action to benefits patients with potentially quick acting and well tolerated new treatment option.
SELTA was isolated from a healthy individual, suggesting the potential for limited off-target effects and toxicity.
Compelling animal data in several inflammation models suggests the potential for development in multiple autoimmune diseases.
Exclusive license option from Northwestern University.
Leadership team of experienced translational research and biopharmaceutical professionals.
Psoriasis as a lead indication enables a risk-mitigated opportunity with an accessible patient population and well-established endpoints – efficiently achieve clinically meaningful milestones.
Founder & Chief Scientific Officer
Chief Executive Officer
Chief Business Officer
Founder & Director of Medical Affairs
